This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: September 29, 2006
Last updated: February 12, 2007
Last verified: February 2007
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Condition Intervention Phase
Pterygia Drug: Topical Cyclosporine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:

Further study details as provided by Innovative Medical:


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00383396

United States, Florida
Dr. Schechter
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute
  More Information Identifier: NCT00383396     History of Changes
Other Study ID Numbers: 1963
Study First Received: September 29, 2006
Last Updated: February 12, 2007

Additional relevant MeSH terms:
Conjunctival Diseases
Eye Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on August 17, 2017